Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.63Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 20, 2025
|% Change Since: 0.00%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with record sales growth, driven by the U.S. and international glaucoma franchises, and positive clinical developments. However, challenges such as LCD impacts, foreign exchange headwinds, and Medicaid rebate effects on corneal health were noted. The company remains optimistic about its strategic plans and financial position.Company Guidance
In the fourth quarter of 2024, Glaukos Corporation reported record consolidated net sales of $105.5 million, marking a 28% increase compared to the previous year. For the full-year 2024, net sales reached $383.5 million, a 22% growth from 2023. The company has set a net sales guidance range of $475 million to $485 million for 2025. A significant driver of this growth was the U.S. glaucoma franchise, particularly the iDose TR, which contributed to record fourth-quarter net sales of $56.3 million, a 45% year-over-year increase. The international glaucoma franchise also delivered strong results, with net sales of $27.9 million, reflecting a 28% growth. For the corneal health franchise, net sales were $21.4 million. Glaukos remains focused on expanding its market presence and advancing its innovative platforms to sustain momentum into 2025, despite anticipated headwinds in some regions and segments.Record Fourth Quarter and Full-Year 2024 Sales
Glaukos reported record fourth quarter consolidated net sales of $105.5 million, up 28% year-over-year, and full-year 2024 consolidated net sales of $383.5 million, up 22% from 2023.
Strong Growth in U.S. Glaucoma Franchise
U.S. glaucoma franchise delivered record fourth quarter net sales of $56.3 million, achieving 45% year-over-year growth, driven by iDose TR.
Positive Clinical Developments for iDose TR
Announced positive 36-month follow-up analysis of iDose TR’s Phase III trials and commenced Phase 2b/3 program for iDose TREX.
Strong International Glaucoma Franchise Performance
International glaucoma franchise delivered record net sales of $27.9 million, with 28% year-over-year growth on a reported basis.
NDA Submission for Epioxa
Submitted NDA for Epioxa, a next-generation corneal cross-linking therapy for keratoconus, with anticipated FDA approval in 2025.
Solid Financial Position
Ended 2024 with $324 million in cash and equivalents, having retired $287.5 million in convertible senior notes, leaving no debt.
---
GKOS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GKOS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 20, 2025 | $157.36 | ― | ― |
| Nov 04, 2024 | $131.38 | $127.86 | -2.68% |
| Jul 31, 2024 | $117.17 | $117.61 | +0.38% |
| May 01, 2024 | $98.91 | $105.03 | +6.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Glaukos (GKOS) report earnings?
Glaukos (GKOS) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Glaukos (GKOS) earnings time?
Glaukos (GKOS) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is GKOS EPS forecast?
GKOS EPS forecast for the fiscal quarter 2024 (Q4) is -0.38.
---